

Brian O Mahony

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2289333/publications.pdf>

Version: 2024-02-01

41
papers

854
citations

430874
18
h-index

526287
27
g-index

43
all docs

43
docs citations

43
times ranked

685
citing authors

#	ARTICLE	IF	CITATIONS
1	Preparing for tomorrow: Defining a future agenda. Haemophilia, 2022, 28, 35-41.	2.1	4
2	A preliminary application of a haemophilia value framework to emerging therapies in haemophilia. Haemophilia, 2022, 28, 9-18.	2.1	8
3	Comprehensive care on paper only? The challenge for physiotherapy provision in day to day haemophilia practice. Haemophilia, 2021, 27, e284-e286.	2.1	4
4	Non-severe haemophilia: Is it benign? Insights from the PROBE study. Haemophilia, 2021, 27, 17-24.	2.1	16
5	Evidence of a disability paradox in patient-reported outcomes in haemophilia. Haemophilia, 2021, 27, 245-252.	2.1	25
6	A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen. Haemophilia, 2021, 27, 544-562.	2.1	12
7	Patient-relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488.	2.3	20
8	Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre's readiness in United States and EU. Haemophilia, 2021, 27, 511-514.	2.1	13
9	Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time. Haemophilia, 2021, 27, e596-e608.	2.1	3
10	Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment. Haemophilia, 2021, 27, 769-782.	2.1	15
11	Recombinant factor IX-Fc fusion protein in severe hemophilia B: Patient-reported outcomes and health-related quality of life. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12602.	2.3	4
12	Eliminating Panglossian thinking in development of AAV therapeutics. Molecular Therapy, 2021, 29, 3325-3327.	8.2	12
13	Achieving the unimaginable: Health equity in haemophilia. Haemophilia, 2020, 26, 17-24.	2.1	54
14	Telehealth for delivery of haemophilia comprehensive care during the COVID-19 pandemic. Haemophilia, 2020, 26, 984-990.	2.1	31
15	Evolution of Haemophilia Care in Europe: 10 years of the principles of care. Orphanet Journal of Rare Diseases, 2020, 15, 184.	2.7	10
16	Haemophilia care in Europe: Past progress and future promise. Haemophilia, 2020, 26, 752-758.	2.1	3
17	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	3.8	24
18	Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?. Haemophilia, 2020, 26, 931-933.	2.1	24

#	ARTICLE	IF	CITATIONS
19	World Federation of Hemophilia Gene Therapy Registry. Haemophilia, 2020, 26, 563-564.	2.1	28
20	The World Federation of Hemophilia Annual Global Survey 1999â€”2018. Haemophilia, 2020, 26, 591-600.	2.1	50
21	Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies. Haematologica, 2020, 105, 2038-2043.	3.5	21
22	How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia, 2019, 25, 545-557.	2.1	54
23	Exploring regional variations in the cross-cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. Haemophilia, 2019, 25, 365-372.	2.1	11
24	Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. Haemophilia, 2019, 25, 75-83.	2.1	14
25	Patient-centred value framework for haemophilia. Haemophilia, 2018, 24, 873-879.	2.1	17
26	The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. Pilot and Feasibility Studies, 2018, 4, 58.	1.2	34
27	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open, 2018, 8, e021900.	1.9	15
28	Value of prophylaxis vs on-demand treatment: Application of a value framework in hemophilia. Haemophilia, 2018, 24, 755-765.	2.1	20
29	Real-world comparative analysis of bleeding complications and health-related quality of life in patients with haemophilia A and haemophilia B. Haemophilia, 2018, 24, e322-e327.	2.1	8
30	Kreuth ^{IV}: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia, 2017, 23, 370-375.	2.1	15
31	Haemophilia care in Europe - A survey of 37 countries. Haemophilia, 2017, 23, e259-e266.	2.1	22
32	Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies. Haemophilia, 2017, 23, 643-644.	2.1	18
33	Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre- ^{DAA} treatment era. Haemophilia, 2017, 23, 712-720.	2.1	7
34	Assessments of outcome in haemophilia â€” a patient perspective. Haemophilia, 2016, 22, e208-9.	2.1	8
35	Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries. Haemophilia, 2015, 21, 436-443.	2.1	21
36	Haemophilia care in Europe - a survey of 35 countries. Haemophilia, 2013, 19, e239-e247.	2.1	67

#	ARTICLE	IF	CITATIONS
37	A survey of the outcome of prophylaxis, onâ€demand treatment or combined treatment in 18â€35â€year old men with severe haemophilia in six countries. Haemophilia, 2013, 19, 44-50.	2.1	45
38	The Dublin Consensus Statement 2011 on vital issues relating to the collection and provision of blood components and plasmaâ€derived medicinal products. Vox Sanguinis, 2012, 102, 140-143.	1.5	20
39	Haemophilia care in Europe: a survey of 19 countries. Haemophilia, 2011, 17, 35-40.	2.1	27
40	The Dublin Consensus Statement on vital issues relating to the collection of blood and plasma and the manufacture of plasma products. Vox Sanguinis, 2010, 98, 447-450.	1.5	25
41	WFH: back to the future. Haemophilia, 2004, 10, 1-8.	2.1	12